HW Biosciences Reaches In-Depth Industry-Academia-Research Cooperation with the School of Optometry of The Hong Kong Polytechnic University

At the Hong Kong Polytechnic University Nanjing Industry-Academia-Research Cooperation Project Signing Ceremony, HW Biosciences (hubio) officially signed an in-depth industry-academia-research cooperation agreement with the School of Optometry of The Hong Kong Polytechnic University (PolyU Optometry). The project was presented as a key science and technology innovation representative in the field of visual health during the signing ceremony.

The School of Optometry of The Hong Kong Polytechnic University holds a leading international position in terms of scientific research outcomes and clinical resources in ophthalmology and visual science. As the only accredited high-level optometric research base in Hong Kong, its research impact ranks 1st in Asia and 15th globally. Multiple scholars from the School have been named among the world's top optometric researchers, earning a high reputation in international ophthalmic diagnosis, treatment, and visual health innovation.

Leveraging this strong partnership with PolyU Optometry, HW Biosciences will deeply integrate international cutting-edge optometric research capabilities and clinical resources. This collaboration will accelerate the domestic substitution and global expansion of high-end ophthalmic therapeutic devices, bridging laboratory research directly to clinical applications.

HW Biosciences Co., Ltd. (Shanghai) was established in 2021, followed by the founding of HW Biosciences Co., Ltd. (Nanchang) in 2024. As a high-end ophthalmic medical device enterprise integrating R&D, manufacturing, and sales, HW Biosciences gathers top talents across materials science, integrated circuits, software, and clinical medicine. Dedicated to independent innovation, the company aims to build a domestically leading and world-class platform for high-end ophthalmic diagnostic/therapeutic equipment and high-value medical consumables.

The company's core technology, the MeiboRevive™ Vectored Thermal Pulsation System, is grounded in advanced international thermal pulsation therapeutic concepts and incorporates the latest research in human factors engineering. Through systematic analysis and iterative optimization of global and domestic clinical data, HW Biosciences has established a targeted physical treatment framework for dry eye disease that features proprietary intellectual property, tailored Chinese clinical characteristics, and global adaptability.

Currently, HW Biosciences has established a comprehensive product line addressing both domestic and international markets:

• Domestic MeiboRevive™ Vectored Thermal Pulsation System (Models: X36, Y36, Y37): All models have obtained medical device registration certificates from the National Medical Products Administration (NMPA).
  
• Overseas MeiboRevive™ Vectored Thermal Pulsation System (Model: S36): Has successfully secured medical device registration approvals in Canada and Australia, and passed the MDSAP 5-country audit certification.
  
• 
  

To date, the devices have been deployed in clinical use across more than 100 hospitals nationwide. In addition, HW Biosciences has won numerous accolades, including 4th Place and the 'Outstanding Enterprise' award in the Bio-Medicine National Finals of the 14th China Innovation & Entrepreneurship Competition, as well as the 3rd Prize in the Start-up Group of the Jiangxi Regional Competition.

Moving forward, HW Biosciences will continue to empower the vision health industry through technological innovation, delivering more effective and comfortable treatment experiences to patients worldwide.